|
|
TTD Drug ID:
DNC008339
Drug
Information |
Name | JUGLONE | Synonyms | JUGLONE | Indication | Not Available | Experimental | Structure |
Click to save drug structure in 3D MOL format
Click to save drug structure in 2D MOL format
| InChI | 1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H | InChIKey | KQPYUDDGWXQXHS-UHFFFAOYSA-N | Canonical SMILES | C1=CC2=C(C(=O)C=CC2=O)C(=C1)O | Target | Arachidonate 5-lipoxygenase |  | Inhibitor | [1] | Dual specificity phosphatase Cdc25B |  | Inhibitor | [2] | Dual specificity protein phosphatase 1 |  | Inhibitor | [2] | Indoleamine 2,3-dioxygenase |  | Inhibitor | [3] | Ref 1 | J Med Chem. 1997 Nov 7;40(23):3773-80.Simple analogues of anthralin: unusual specificity of structure and antiproliferative activity. To Reference | Ref 2 | Bioorg Med Chem. 2009 Mar 15;17(6):2276-81. Epub 2008 Nov 8.Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. To Reference | Ref 3 | J Med Chem. 2008 Mar 27;51(6):1706-18. Epub 2008 Mar 5.Indoleamine 2,3-dioxygenase is the anticancer target for a novel series of potent naphthoquinone-based inhibitors. To Reference |
Welcome
to sign our Guestbook.
If you
find any error in data or bug in web service, please kindly report it
to Dr.
Zhu.
Dr.
Chen Yuzong
Deputy Director of Center
for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore
All rights reserved.
|